论文部分内容阅读
特非那定是80年代初,由德国赫斯特制药公司研制成功的第一个抗组胺药物,为新一代H_1受体拮抗剂,用于治疗过敏性鼻炎、荨麻疹以及过敏性皮肤病等。特非那定具有无镇静作用(即不易致困倦)和脱敏等特点,因而受到医生患者的一致好评。在欧美等国上市以后,得到迅速推广,在世界范围内广泛应用。 90年代初期,人们发现特非那定与某些药物合用时,会出现比较严重的不良反应。美国食品药品管理局(FDA)曾接到391份医生报告,谈到特非那定引致的严重不良反应,包括死亡病例。于是美国FDA在1997年初发表建议,撤销赫斯特公司生产的特非那定制剂的批
Terfenadine is the first anti-histamine drug developed by Hearst Pharmaceuticals in Germany in the early 1980s as a new generation of H 1 receptor antagonist for the treatment of allergic rhinitis, urticaria and allergic skin diseases Wait. Terfenadine has no sedative effect (that is not easy to cause drowsiness) and desensitization and other characteristics, which are subject to the praise of the doctors patients. After being listed in Europe and the United States and other countries, it has been rapidly popularized and widely used in the world. The early 90s, people found that terfenadine and certain drugs combined, there will be more serious adverse reactions. The U.S. Food and Drug Administration (FDA) has received 391 reports from doctors regarding serious adverse reactions caused by terfenadine, including deaths. So the U.S. FDA issued a proposal in early 1997 to revoke the formulation of terfenadine produced by Hearst